Advertisement

Organisation › Details
Navigo Proteins GmbH, Navigo Precision Targeting business unit
Navigo Proteins is a near-clinical fast-growing biopharmaceutical company focused on Precision Medicine and particularly next generation radiotheranostics based on using its proprietary Affilin® platform. Affilins® are novel target-binding proteins, combining the advantages of antibodies and peptides. The growing Affilin® portfolio, backed by unique pre-clinical data, tackles key challenges in targeted therapeutics, achieving exceptional tumor-specific accumulation and favorable biodistribution. Collaborations in the Radiopharmaceutical industry with strong players like ITM, as well as in-house programs drive the development of Affilins® for targeted radioligand therapy and imaging. The ultimate aim at Navigo Proteins is to deliver best-in-class therapies and lifesaving products to patients faster. The high modularity of the Navigo platform allows faster innovation cycles building on proven and tested components. *
![]() |
Start | 2017-02-03 renamed |
Group | UV-Cap (Vetter family office) (Group) | |
Predecessor | Scil Proteins GmbH | |
![]() |
Industry | BIOTECH |
Industry 2 | RADIOPHARMACEUTICAL (RPT) | |
![]() |
Person | Afflerbach, Henning (Coral BioNet 201205 CBO at Scil Proteins) |
Person 2 | Vetter, Udo J. (UV-Cap 201702 Founder + Managing Director) | |
![]() |
Region | Halle (Saale) |
Country | Germany | |
Street | 1 Heinrich-Damerow-Str. | |
City | 06120 Halle (Saale) | |
Tel | +49-345-27996-330 | |
Address record changed: 2025-04-01 | ||
Basic data | Employees | C: 51 to 100 (2011-02-18) |
* Document for »About Section«: Navigo Proteins GmbH. (4/1/25). "Press Release: Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics". Halle (Saale) & Mol. | ||
Record changed: 2025-04-01 |
Advertisement

More documents for UV-Cap (Vetter family office) (Group)
- [1] Navigo Proteins GmbH. (4/1/25). "Press Release: Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics". Halle (Saale) & Mol....
- [2] Veraxa Biotech AG. (12/12/24). "Press Release: Veraxa Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates". Heidelberg & Halle (Saale)....
- [3] Navigo Proteins GmbH. (9/6/23). "Press Release: Navigo Proteins and Nostrum Biodiscovery Announce a Research Collaboration to Enhance Affilin Ligand Discovery Using Cutting-edge AI and Molecular Modeling Techniques". Halle (Saale) & Barcelona....
- [4] Navigo Proteins GmbH. (9/26/22). "Press Release: Navigo and Mannin Sign Agreement to Develop Innovative Affinity Ligand Against a Novel Drug for the Treatment of COVID-19". Halle (Saale)....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top